Targeted proteomics strategy applied to biomarker evaluation

The evaluation of biomarker candidates, involving quantitative measurement of a large number of proteins in bodily fluids, remains the main obstruction in the development of a biomarker validation pipeline. Although immunoassays are commonly used, high‐throughput and multiplex‐capable methods are required for expediting the evaluation process. MS‐based approaches employing targeted proteomic strategies provide not only a sensitive, but in addition a precise quantification tool, which is versatile, systematic, and scalable. Its capability of multiplexing hundreds of targets facilitate a cost‐effective and rapid evaluation and is especially useful during the early stage of the process where a large list of candidate biomarkers must be triaged before entering validation studies. The robustness requirement for the methods also mandates a high degree of selectivity to analyze complex clinical samples. Improvement in the selectivity of LC‐MS methods has been achieved by adopting high‐resolution and high‐accuracy mass analyzers to perform quantitative analyses with a novel method called parallel reaction monitoring. This article discusses the design and performance of biomarker evaluation studies using targeted proteomics strategies and the implementation of recent technology developments.

[1]  Christoph H Borchers,et al.  Multiplexed MRM‐based quantitation of candidate cancer biomarker proteins in undepleted and non‐enriched human plasma , 2013, Proteomics.

[2]  T. Rezai,et al.  Selected reaction monitoring-mass spectrometric immunoassay responsive to parathyroid hormone and related variants. , 2010, Clinical chemistry.

[3]  Leigh Anderson,et al.  Quantitative Mass Spectrometric Multiple Reaction Monitoring Assays for Major Plasma Proteins* , 2006, Molecular & Cellular Proteomics.

[4]  Henry H. N. Lam,et al.  A database of mass spectrometric assays for the yeast proteome , 2008, Nature Methods.

[5]  John D. Venable,et al.  Automated approach for quantitative analysis of complex peptide mixtures from tandem mass spectra , 2004, Nature Methods.

[6]  R. Aebersold,et al.  Selected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions , 2012, Nature Methods.

[7]  R. Beavis,et al.  An Improved Model for Prediction of Retention Times of Tryptic Peptides in Ion Pair Reversed-phase HPLC , 2004, Molecular & Cellular Proteomics.

[8]  S. Carr,et al.  Quantitative analysis of peptides and proteins in biomedicine by targeted mass spectrometry , 2013, Nature Methods.

[9]  Darryl B. Hardie,et al.  Advances in multiplexed MRM-based protein biomarker quantitation toward clinical utility. , 2014, Biochimica et biophysica acta.

[10]  Bruno Domon,et al.  Considerations on selected reaction monitoring experiments: Implications for the selectivity and accuracy of measurements , 2012, Proteomics. Clinical applications.

[11]  S. Gygi,et al.  ms3 eliminates ratio distortion in isobaric multiplexed quantitative , 2011 .

[12]  Ludovic C. Gillet,et al.  Quantitative measurements of N‐linked glycoproteins in human plasma by SWATH‐MS , 2013, Proteomics.

[13]  Susan E Abbatiello,et al.  Automated detection of inaccurate and imprecise transitions in peptide quantification by multiple reaction monitoring mass spectrometry. , 2010, Clinical chemistry.

[14]  Juncong Yang,et al.  MRM‐based multiplexed quantitation of 67 putative cardiovascular disease biomarkers in human plasma , 2012, Proteomics.

[15]  Lennart Martens,et al.  PRIDE: new developments and new datasets , 2007, Nucleic Acids Res..

[16]  Ruedi Aebersold,et al.  Statistical protein quantification and significance analysis in label-free LC-MS experiments with complex designs , 2012, BMC Bioinformatics.

[17]  Tushar Sakpal,et al.  Sample Size Estimation in Clinical Trial , 2010, Perspectives in clinical research.

[18]  Robertson Craig,et al.  Open source system for analyzing, validating, and storing protein identification data. , 2004, Journal of proteome research.

[19]  Ludovic C. Gillet,et al.  Targeted Data Extraction of the MS/MS Spectra Generated by Data-independent Acquisition: A New Concept for Consistent and Accurate Proteome Analysis* , 2012, Molecular & Cellular Proteomics.

[20]  Z. Mester,et al.  Review of applications of high-field asymmetric waveform ion mobility spectrometry (FAIMS) and differential mobility spectrometry (DMS). , 2007, The Analyst.

[21]  M. Galceran,et al.  Liquid chromatography/tandem mass spectrometry (highly selective selected reaction monitoring) for the analysis of isopropylthioxanthone in packaged food. , 2008, Journal of chromatography. A.

[22]  T. Klaassen,et al.  Validated quantitation method for a peptide in rat serum using liquid chromatography/high-field asymmetric waveform ion mobility spectrometry. , 2009, Rapid communications in mass spectrometry : RCM.

[23]  P. Karakiewicz,et al.  Prostate cancer: 5. Diagnostic tools for early detection. , 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[24]  Derek J. Bailey,et al.  Parallel Reaction Monitoring for High Resolution and High Mass Accuracy Quantitative, Targeted Proteomics* , 2012, Molecular & Cellular Proteomics.

[25]  Katja Köhler,et al.  Validation Processes of Protein Biomarkers in Serum—A Cross Platform Comparison , 2012, Sensors.

[26]  Scott Peterman,et al.  Highly multiplexed targeted proteomics using precise control of peptide retention time , 2012, Proteomics.

[27]  R. Aebersold,et al.  Perspectives of targeted mass spectrometry for protein biomarker verification. , 2009, Current opinion in chemical biology.

[28]  Roger E Bumgarner,et al.  Sample size for detecting differentially expressed genes in microarray experiments , 2004, BMC Genomics.

[29]  S. Sauer,et al.  Protein Sets Define Disease States and Predict In Vivo Effects of Drug Treatment* , 2013, Molecular & Cellular Proteomics.

[30]  B. Domon,et al.  Mass spectrometry–based detection and quantification of plasma glycoproteins using selective reaction monitoring , 2012, Nature Protocols.

[31]  D M Desiderio,et al.  Preparation of stable isotope-incorporated peptide internal standards for field desorption mass spectrometry quantification of peptides in biologic tissue. , 1983, Biomedical mass spectrometry.

[32]  Bruno Domon,et al.  Selectivity of LC-MS/MS analysis: implication for proteomics experiments. , 2013, Journal of proteomics.

[33]  B. Ueberheide,et al.  Detection and correction of interference in SRM analysis. , 2013, Methods.

[34]  Daniel B. Martin,et al.  Computational prediction of proteotypic peptides for quantitative proteomics , 2007, Nature Biotechnology.

[35]  M. Mann,et al.  Mass Spectrometry-based Proteomics Using Q Exactive, a High-performance Benchtop Quadrupole Orbitrap Mass Spectrometer* , 2011, Molecular & Cellular Proteomics.

[36]  Henry H. N. Lam,et al.  PeptideAtlas: a resource for target selection for emerging targeted proteomics workflows , 2008, EMBO reports.

[37]  B. Domon,et al.  Selected reaction monitoring applied to proteomics. , 2011, Journal of mass spectrometry : JMS.

[38]  B. Domon,et al.  Targeted Proteomic Quantification on Quadrupole-Orbitrap Mass Spectrometer* , 2012, Molecular & Cellular Proteomics.

[39]  C. Borchers,et al.  Comparison of standard- and nano-flow liquid chromatography platforms for MRM-based quantitation of putative plasma biomarker proteins , 2012, Analytical and Bioanalytical Chemistry.